DiaMedica Therapeutics Stock (NASDAQ: DMAC)

DiaMedica Therapeutics

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

xr:d:DAFf-XLMTok:2,j:45108184879,t:23041309

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CURB

DMAC

FAST

UROY

WEST

This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Equities

Penny Stocks

Offerings

General

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a 

DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199

Long Ideas

Small Cap

Insider Trades

OABI

The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics Inc

Press Releases

DiaMedica Therapeutics Upcoming Conference Participation

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Comments

DiaMedica Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga